دورية أكاديمية
Treatment of Chronic HCV Infection with Direct Acting Antivirals
| العنوان: | Treatment of Chronic HCV Infection with Direct Acting Antivirals |
|---|---|
| المؤلفون: | Bekhbold Dashtseren, Zulkhuu Genden, Odgerel Oidovsambuu, Anir Enkhbat, Ganbolor Jargalsaikhan, Sumiya Byambabaatar, Myammarsuren Shagdarsuren, Altankhuu Murdorj, Oyungerel Ravjir, Naranbaatar Dashdorj, Naranjargal Dashdorj, Dagvadorj Yagaanbuyant, Batbaatar Gunchin |
| المصدر: | Central Asian Journal of Medical Sciences, Vol 7, Iss 3, Pp 222-230 (2021) |
| بيانات النشر: | Mongolian National University of Medical Sciences, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Medicine LCC:Medicine (General) |
| مصطلحات موضوعية: | direct-acting antivirals, hepatitis c, ledipasvir, sofosbuvir, Medicine, Medicine (General), R5-920 |
| الوصف: | Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs). Methods: Based on the Liver Center database, we studied the treatment effect of Sofosbuvir 400 mg/Ledipasvir 90 mg in 1109 patients with chronic hepatitis C virus infection during the time period from December 2015 to December, 2018. Results: In patients treated with Sofosbuvir/Ledipasvir, the sustained viral load (SVR12) was 97.9% (1086/1109) 12 weeks after the treatment. The SVR12 was 99.2% (845/851) in HCV-infected non-cirrhotic patients, 93.4% (241/258) in patients with cirrhosis, and 80% (8/10) among patients treated for liver cancer. The SVR12 (19/25) was lowered to 76% at 12 weeks of treatment with Sofosbuvir 400 mg/ Daclatasvir 60 mg in DAA-failure patients 23/1109 (2.07%). Conclusions: SVR12 rates in non-cirrhotic and cirrhotic patients were 99.2% and 93.4%, respectively, while it was 80% in liver cancer patients after DAA treatment. As for patients with viral relapse, 76% of them were successfully retreated with second-line DAA treatment. During the DAA treatment, only 17.6% of all patients had some adverse effects related to DAA treatment, thus, DAA treatment is suitable for Mongolian patients and has less adverse effects. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2413-8681 2414-9772 |
| العلاقة: | https://www.mongoliajol.info/index.php/CAJMS/article/view/2986Test; https://doaj.org/toc/2413-8681Test; https://doaj.org/toc/2414-9772Test |
| DOI: | 10.24079/cajms.2021.09.007 |
| الوصول الحر: | https://doaj.org/article/26b7158218604ab8991b1354a58f0746Test |
| رقم الانضمام: | edsdoj.26b7158218604ab8991b1354a58f0746 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 24138681 24149772 |
|---|---|
| DOI: | 10.24079/cajms.2021.09.007 |